Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | UK-based CLL clinical trials to look forward to

Daniel Catovsky • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Rituximab Venetoclax

Speaking from the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, held in Barcelona, Spain, Daniel Catovsky, MD, DSc, FRCP, FRCPath, FMedSci, of the Institute of Cancer Research, London, UK, discusses what clinical trials he’s excited about at the moment in the chronic lymphocytic leukemia space, which are looking at novel combinations comprising agents such as ibrutinib, rituximab and venetoclax.

More from Daniel Catovsky

1:49
The future of CLL: managing new toxicities and improved categorization
Daniel Catovsky • 25 Oct 2018
1:16
Thoughts on the use of MRD in CLL
Daniel Catovsky • 25 Oct 2018

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals